Screening Protein Prognostic Biomarkers for Stomach Adenocarcinoma Based on The Cancer Proteome Atlas

被引:12
作者
Zheng, Guo-Liang [1 ]
Zhang, Guo-Jun [2 ]
Zhao, Yan [1 ]
Zheng, Zhi-chao [1 ]
机构
[1] Canc Hosp China Med Univ, Liaoning Canc Hosp & Inst, Dept Gastr Surg, Shenyang, Peoples R China
[2] China Med Univ, Coll Basic Med Sci, Dept Pathophysiol, Shenyang, Peoples R China
基金
中国国家自然科学基金;
关键词
stomach adenocarcinoma; TCGA database; TCPA database; protein; prognosis; DOUBLE-BLIND; VI; GLYCOLYSIS; OVEREXPRESSION; APOPTOSIS; TIGAR; P53;
D O I
10.3389/fonc.2022.901182
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The objective was to construct a prognostic risk model of stomach adenocarcinoma (STAD) based on The Cancer Proteome Atlas (TCPA) to search for prognostic biomarkers. Protein data and clinical data on STAD were downloaded from the TCGA database, and differential expressions of proteins between carcinoma and para-carcinoma tissues were screened using the R package. The STAD data were randomly divided into a training set and a testing set in a 1:1 ratio. Subsequently, a linear prognostic risk model of proteins was constructed using Cox regression analysis based on training set data. Based on the scores of the prognostic model, sampled patients were categorized into two groups: a high-risk group and a low-risk group. Using the testing set and the full sample, ROC curves and K-M survival analysis were conducted to measure the predictive power of the prognostic model. The target genes of proteins in the prognostic model were predicted and their biological functions were analyzed. A total of 34 differentially expressed proteins were screened (19 up-regulated, 15 down-regulated). Based on 176 cases in the training set, a prognostic model consisting of three proteins (COLLAGEN VI, CD20, TIGAR) was constructed, with moderate prediction accuracy (AUC=0.719). As shown by the Kaplan-Meier and survival status charts, the overall survival rate of the low-risk group was better than that of the high-risk group. Moreover, a total of 48 target proteins were identified to have predictive power, and the level of proteins in hsa05200 (Pathways in cancer) was the highest. According to the results of the Univariate and multivariate COX analysis, tri-protein was identified as an independent prognostic factor. Therefore, the tri-protein prognostic risk model can be used to predict the likelihood of STAD and guide clinical treatment.
引用
收藏
页数:10
相关论文
共 22 条
[1]   Identification of the TP53-induced glycolysis and apoptosis regulator in various stages of colorectal cancer patients [J].
Al-Khayal, Khayal ;
Abdulla, Maha ;
Al-Obeed, Omar ;
Al Kattan, Wael ;
Zubaidi, Ahmad ;
Vaali-Mohammed, Mansor-Ali ;
Alsheikh, Abdulmalik ;
Ahmad, Rehan .
ONCOLOGY REPORTS, 2016, 35 (03) :1281-1286
[2]   CELL ATTACHMENT PROPERTIES OF COLLAGEN TYPE-VI AND ARG-GLY-ASP DEPENDENT BINDING TO ITS ALPHA-2(VI) AND ALPHA-3(VI) CHAINS [J].
AUMAILLEY, M ;
MANN, K ;
VONDERMARK, H ;
TIMPL, R .
EXPERIMENTAL CELL RESEARCH, 1989, 181 (02) :463-474
[3]  
Bang YJ, 2010, LANCET, V376, P1302
[4]   The collagen VI-related myopathies: muscle meets its matrix [J].
Bonnemann, Carsten G. .
NATURE REVIEWS NEUROLOGY, 2011, 7 (07) :379-390
[5]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[6]   Gastric Cancer: How Can We Reduce the Incidence of this Disease? [J].
den Hoed C.M. ;
Kuipers E.J. .
Current Gastroenterology Reports, 2016, 18 (7) :1-8
[7]   MOLECULAR-CLONING OF THE HUMAN B-CELL CD20 RECEPTOR PREDICTS A HYDROPHOBIC PROTEIN WITH MULTIPLE TRANSMEMBRANE DOMAINS [J].
EINFELD, DA ;
BROWN, JP ;
VALENTINE, MA ;
CLARK, EA ;
LEDBETTER, JA .
EMBO JOURNAL, 1988, 7 (03) :711-717
[8]   Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment [J].
Iyengar, P ;
Espina, V ;
Williams, TW ;
Lin, Y ;
Berry, D ;
Jelicks, LA ;
Lee, H ;
Temple, K ;
Graves, R ;
Pollard, J ;
Chopra, N ;
Russell, RG ;
Sasisekharan, R ;
Trock, BJ ;
Lippman, M ;
Calvert, VS ;
Petricoin, EF ;
Liotta, L ;
Dadachova, E ;
Pestell, RG ;
Lisanti, MP ;
Bonaldo, P ;
Scherer, PE .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (05) :1163-1176
[9]   Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial [J].
Kang, Yoon-Koo ;
Boku, Narikazu ;
Satoh, Taroh ;
Ryu, Min-Hee ;
Chao, Yee ;
Kato, Ken ;
Chung, Hyun Cheol ;
Chen, Jen-Shi ;
Muro, Kei ;
Kang, Won Ki ;
Yeh, Kun-Huei ;
Yoshikawa, Takaki ;
Oh, Sang Cheul ;
Bai, Li-Yuan ;
Tamura, Takao ;
Lee, Keun-Wook ;
Hamamoto, Yasuo ;
Kim, Jong Gwang ;
Chin, Keisho ;
Oh, Do-Youn ;
Minashi, Keiko ;
Cho, Jae Yong ;
Tsuda, Masahiro ;
Chen, Li-Tzong .
LANCET, 2017, 390 (10111) :2461-2471
[10]  
Küppers R, 2012, J CLIN INVEST, V122, P3439, DOI [10.1172/JCI61245, 10.1172/JCI6124.5]